KUALA LUMPUR: Duopharma Biotech Bhd
and the government have executed the agreement to procure insulin medicines via direct negotiation for RM375.17 million, a Bursa Malaysia filing said.
The company said wholly-owned subsidiary Duopharma Marketing Sdn Bhd (DMktg) will supply and deliver the products to the Health Ministry while Biocon Sdn Bhd, the manufacturer, will pack and label the products under the agreement.
Biocon's human insulin formulation will be supplied to all MoH hospitals, district health offices and health clinics.
The three-year agreement is from Apr 29, 2022 to Apr 28, 2025. It may be extended based on terms and conditions to be agreed on by the parties.
Malaysia has an estimated 3.9 million diabetics, with 420,000 using human insulin in the government hospitals and clinics.
DMktg and Biocon hope to improve diabetes management in the country by providing high quality and cost-effective biosimilar insulins. - Bernama
